JP2024515577A - 修飾された顆粒球コロニー刺激因子(g-csf)及びこれに結合するキメラサイトカイン受容体 - Google Patents

修飾された顆粒球コロニー刺激因子(g-csf)及びこれに結合するキメラサイトカイン受容体 Download PDF

Info

Publication number
JP2024515577A
JP2024515577A JP2023562188A JP2023562188A JP2024515577A JP 2024515577 A JP2024515577 A JP 2024515577A JP 2023562188 A JP2023562188 A JP 2023562188A JP 2023562188 A JP2023562188 A JP 2023562188A JP 2024515577 A JP2024515577 A JP 2024515577A
Authority
JP
Japan
Prior art keywords
receptor
cells
cell
optionally
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515577A5 (cg-RX-API-DMAC7.html
Inventor
マーティン ジェイ. ブーランジェ
ブラッド ネルソン
キャメロン パウエル
ミーガン フラー
Original Assignee
プロヴィンシャル ヘルス サービシーズ オーソリティ
ユーヴィック インダストリー パートナーシップス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロヴィンシャル ヘルス サービシーズ オーソリティ, ユーヴィック インダストリー パートナーシップス インコーポレイテッド filed Critical プロヴィンシャル ヘルス サービシーズ オーソリティ
Publication of JP2024515577A publication Critical patent/JP2024515577A/ja
Publication of JP2024515577A5 publication Critical patent/JP2024515577A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023562188A 2021-04-07 2022-04-07 修飾された顆粒球コロニー刺激因子(g-csf)及びこれに結合するキメラサイトカイン受容体 Pending JP2024515577A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163171980P 2021-04-07 2021-04-07
US202163172025P 2021-04-07 2021-04-07
US202163171933P 2021-04-07 2021-04-07
US202163171950P 2021-04-07 2021-04-07
US63/172,025 2021-04-07
US63/171,933 2021-04-07
US63/171,950 2021-04-07
US63/171,980 2021-04-07
PCT/CA2022/050540 WO2022213208A1 (en) 2021-04-07 2022-04-07 Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same

Publications (2)

Publication Number Publication Date
JP2024515577A true JP2024515577A (ja) 2024-04-10
JP2024515577A5 JP2024515577A5 (cg-RX-API-DMAC7.html) 2025-04-15

Family

ID=83544985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562188A Pending JP2024515577A (ja) 2021-04-07 2022-04-07 修飾された顆粒球コロニー刺激因子(g-csf)及びこれに結合するキメラサイトカイン受容体

Country Status (9)

Country Link
US (1) US20240254182A1 (cg-RX-API-DMAC7.html)
EP (1) EP4320168A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024515577A (cg-RX-API-DMAC7.html)
KR (1) KR20240004453A (cg-RX-API-DMAC7.html)
AU (1) AU2022254143A1 (cg-RX-API-DMAC7.html)
CA (1) CA3213795A1 (cg-RX-API-DMAC7.html)
IL (1) IL307272A (cg-RX-API-DMAC7.html)
MX (1) MX2023011880A (cg-RX-API-DMAC7.html)
WO (1) WO2022213208A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250057883A1 (en) * 2021-12-23 2025-02-20 The Trustees Of The University Of Pennsylvania Controllable stimulation of genetically engineered lymphocytes for the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519478A (ja) * 2000-01-10 2003-06-24 マキシゲン・ホールディングズ・リミテッド G−csf結合体
JP2012503014A (ja) * 2008-09-19 2012-02-02 マキシジェン, インコーポレイテッド マルチ−peg化顆粒球コロニー刺激因子(g−csf)変異体の投与による放射線誘発好中球減少症の処置のための方法
JP2018526020A (ja) * 2015-09-11 2018-09-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン/受容体ペア
WO2021068074A1 (en) * 2019-10-08 2021-04-15 Zymeworks Inc. Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695869B2 (en) * 1993-04-06 1998-08-27 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
US20200397821A1 (en) * 2017-03-03 2020-12-24 Exuma Biotech Corp Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
AU2019227979B2 (en) * 2018-03-02 2024-09-05 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
WO2021068068A1 (en) * 2019-10-08 2021-04-15 Provincial Health Services Authority Chimeric cytokine receptors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519478A (ja) * 2000-01-10 2003-06-24 マキシゲン・ホールディングズ・リミテッド G−csf結合体
JP2012503014A (ja) * 2008-09-19 2012-02-02 マキシジェン, インコーポレイテッド マルチ−peg化顆粒球コロニー刺激因子(g−csf)変異体の投与による放射線誘発好中球減少症の処置のための方法
JP2018526020A (ja) * 2015-09-11 2018-09-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン/受容体ペア
WO2021068074A1 (en) * 2019-10-08 2021-04-15 Zymeworks Inc. Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. BIOL. CHEM., vol. 274, JPN6026027991, 1999, pages 17445 - 17451, ISSN: 0005901463 *

Also Published As

Publication number Publication date
KR20240004453A (ko) 2024-01-11
AU2022254143A1 (en) 2023-11-23
MX2023011880A (es) 2024-01-05
WO2022213208A1 (en) 2022-10-13
US20240254182A1 (en) 2024-08-01
CA3213795A1 (en) 2022-10-13
IL307272A (en) 2023-11-01
EP4320168A1 (en) 2024-02-14
EP4320168A4 (en) 2025-08-20

Similar Documents

Publication Publication Date Title
JP2026054469A (ja) リンパ球の改変および送達のための方法および組成物
JP7708745B2 (ja) 顆粒球コロニー刺激因子受容体(g-csfr)の改変された細胞外ドメイン及びそれに結合するサイトカイン
US12103956B2 (en) Suicide module compositions and methods
JP2025163198A (ja) キメラサイトカイン受容体
US20260103503A1 (en) A2/ny-eso-1 specific t cell receptors and uses thereof
TW202146431A (zh) 用於經工程化細胞之嵌合受體
KR20230010228A (ko) 자연 살해 세포를 표적으로 하는 키메라 항원 수용체 (cars)
WO2024110751A1 (en) Constitutively active chimeric antigen receptor for treg cell survival and/or persistence
TW202334398A (zh) 組成型細胞激素受體
US20240254182A1 (en) Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same
CN121586727A (zh) 组成型细胞因子受体
WO2024133472A1 (en) Constitutive cytokine receptors
JP2023021361A (ja) メラノーマの処置のための方法および組成物
KR20250036739A (ko) 소분자 약물 접합체와 car-발현 세포독성 림프구의 조합물 및 사용 방법
KR20200036874A (ko) 암 치료를 위한 방법 및 조성물
CN117425679A (zh) 经修饰的粒细胞集落刺激因子(g-csf)和结合其的嵌合细胞因子受体
US20240052015A1 (en) Inducible signalling protein
Mazhara Immunostimulatory activity and antitumor efficacy of mSOT201 immunocytokine
WO2024215989A1 (en) ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250401

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260706

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260722